F8 and hemophilia A: A significantly distinct landscape is observed for agents in active clinical trials for Hemophilia A. The largest proportion of active ingredients in the investigative hemostats under active clinical trials is AAV therapy, followed closely by anti‐TFPI antibodies and FVIII mimetic antibodies.